Properties of Pleural Mesothelial Cells in Idiopathic Pulmonary Fibrosis and Cryptogenic Organizing Pneumonia.
CCL18
Idiopathic Pulmonary Fibrosis
LRRN4
Pleural Mesothelial Cell
Uroplakin 3B
Journal
Journal of Korean medical science
ISSN: 1598-6357
Titre abrégé: J Korean Med Sci
Pays: Korea (South)
ID NLM: 8703518
Informations de publication
Date de publication:
07 Aug 2023
07 Aug 2023
Historique:
received:
02
01
2023
accepted:
03
04
2023
medline:
9
8
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Profibrotic properties of pleural mesothelial cells may play an important role in the fibrosis activity in idiopathic pulmonary fibrosis (IPF). The purpose of this study was to compare the expression of pleural mesothelial cell markers in IPF and cryptogenic organizing pneumonia (COP), with an assumption that increased expression implies increase in fibrosis. Twenty IPF lung samples were stained by immunohistochemistry for the pleural mesothelial cell markers: leucine rich repeat neuronal 4 (LRRN4), uroplakin 3B, CC-chemokine ligand 18, and laminin-5. Nine COP lung samples were used as controls. A semi-quantitative analysis was performed to compare markers expression in IPF and COP. LRRN4 expression was found in epithelial lining cells along the honeycombing and fibroblastic foci in IPF, but not in the fibrotic interstitial lesion and airspace filling fibrous tufts in COP. We found a significant decrease in baseline forced vital capacity when LRRN4 expression was increased in honeycombing epithelial cells and fibroblastic foci. LRRN4 expression patterns in IPF are distinct from those in COP. Our findings suggest that mesothelial cell profibrotic property may be an important player in IPF pathogenesis and may be a clue in the irreversibility of fibrosis in IPF.
Sections du résumé
BACKGROUND
BACKGROUND
Profibrotic properties of pleural mesothelial cells may play an important role in the fibrosis activity in idiopathic pulmonary fibrosis (IPF). The purpose of this study was to compare the expression of pleural mesothelial cell markers in IPF and cryptogenic organizing pneumonia (COP), with an assumption that increased expression implies increase in fibrosis.
METHODS
METHODS
Twenty IPF lung samples were stained by immunohistochemistry for the pleural mesothelial cell markers: leucine rich repeat neuronal 4 (LRRN4), uroplakin 3B, CC-chemokine ligand 18, and laminin-5. Nine COP lung samples were used as controls. A semi-quantitative analysis was performed to compare markers expression in IPF and COP.
RESULTS
RESULTS
LRRN4 expression was found in epithelial lining cells along the honeycombing and fibroblastic foci in IPF, but not in the fibrotic interstitial lesion and airspace filling fibrous tufts in COP. We found a significant decrease in baseline forced vital capacity when LRRN4 expression was increased in honeycombing epithelial cells and fibroblastic foci.
CONCLUSION
CONCLUSIONS
LRRN4 expression patterns in IPF are distinct from those in COP. Our findings suggest that mesothelial cell profibrotic property may be an important player in IPF pathogenesis and may be a clue in the irreversibility of fibrosis in IPF.
Identifiants
pubmed: 37550810
pii: 38.e242
doi: 10.3346/jkms.2023.38.e242
pmc: PMC10412035
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e242Informations de copyright
© 2023 The Korean Academy of Medical Sciences.
Déclaration de conflit d'intérêts
The authors have no potential conflicts of interest to disclose.
Références
J Clin Oncol. 1999 May;17(5):1474-81
pubmed: 10334533
Insights Imaging. 2014 Jun;5(3):347-64
pubmed: 24844883
J Thorac Dis. 2015 Jun;7(6):964-80
pubmed: 26150910
Respir Res. 2018 Feb 22;19(1):32
pubmed: 29471816
Biochim Biophys Acta Mol Cell Res. 2020 Nov;1867(11):118806
pubmed: 32739525
Respir Med. 2014 Sep;108(9):1377-86
pubmed: 25066934
Int J Mol Sci. 2020 Jan 14;21(2):
pubmed: 31947693
EMBO Mol Med. 2020 Aug 7;12(8):e12034
pubmed: 32597014
Chest. 2016 Aug;150(2):299-306
pubmed: 26997242
Am J Respir Crit Care Med. 2004 Jan 1;169(1):27-33
pubmed: 14500258
Am J Pathol. 2020 Dec;190(12):2427-2435
pubmed: 32919981
Eur Respir J. 2012 Jan;39(1):133-40
pubmed: 21737551
PLoS One. 2011;6(10):e25391
pubmed: 21984916
Eur Respir J. 2011 Dec;38(6):1355-60
pubmed: 21778167
Immunology. 2012 Apr;135(4):287-98
pubmed: 22117697
J Pathol. 2012 Jan;226(2):229-40
pubmed: 21959952
Am J Respir Crit Care Med. 2009 Apr 15;179(8):717-23
pubmed: 19179488
Biochim Biophys Acta Mol Cell Res. 2018 Sep;1865(9):1201-1210
pubmed: 29842893
Physiol Rev. 2016 Oct;96(4):1567-91
pubmed: 27630174
Lung. 2018 Oct;196(5):561-567
pubmed: 30097721
Semin Respir Crit Care Med. 2012 Oct;33(5):462-75
pubmed: 23001801
Front Physiol. 2014 Aug 01;5:284
pubmed: 25136318